Arcturus Therapeutics Holdings Inc. (ARCT)

NGM – Real Time Price. Currency in USD

7.85

+0.33 (4.39%)

Market open: Aug 12, 2026, 12:57 PM EDT

7.47

-0.05 (-0.66%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

12.08.2026

Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline

Arcturus Therapeutics NASDAQ: ARCT is positioning its mRNA platform around two rare-disease programs targeting cystic fibrosis and ornithine transcarbamylase deficiency, while its vaccine business is intended to help support therapeutic development, President and CEO Joseph Payne said during a Canaccord discussion.

07.08.2026

Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2026 Earnings Call Transcript

06.08.2026

Arcturus Therapeutics (ARCT) Reports Q2 Loss, Beats Revenue Estimates

Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.84 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to a loss of $0.34 per share a year ago.

06.08.2026

Arcturus Therapeutics Q2 Earnings Call Highlights

Arcturus Therapeutics NASDAQ: ARCT reported progress across its rare-disease pipeline during the second quarter of 2026, completed enrollment and dosing in its Phase II ornithine transcarbamylase deficiency study, and regained global rights to its KOSTAIVE COVID-19 vaccine and self-amplifying mRNA platform following the end of its collaboration with CSL Seqirus.

06.08.2026

Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced its financial results for the quarter ended June 30, 2026, and provided corporate updates. “We are encouraged by the continued progress of our ARCT-032 Phase 2 cystic fibrosis study, with active screening and ongoing enrollment across sites in the United States,.

Videos

No Data

There is no data to display

Press releases

06.08.2026

Arcturus Therapeutics Holdings Inc. (ARCT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Arcturus Therapeutics Holdings Inc. (ARCT)

Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline

Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2026 Earnings Call Transcript

Arcturus Therapeutics (ARCT) Reports Q2 Loss, Beats Revenue Estimates

Arcturus Therapeutics Q2 Earnings Call Highlights

Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress

Videos

No Data

Press releases

Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress

Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline

Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2026 Earnings Call Transcript

Arcturus Therapeutics (ARCT) Reports Q2 Loss, Beats Revenue Estimates

Arcturus Therapeutics Q2 Earnings Call Highlights

Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress

Videos

No Data

Press releases

Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress

Search stocks

Arcturus Therapeutics Holdings Inc. (ARCT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Arcturus Therapeutics Holdings Inc. (ARCT)

Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline

Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2026 Earnings Call Transcript

Arcturus Therapeutics (ARCT) Reports Q2 Loss, Beats Revenue Estimates

Arcturus Therapeutics Q2 Earnings Call Highlights

Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress

Videos

No Data

Press releases

Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress

Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline

Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2026 Earnings Call Transcript

Arcturus Therapeutics (ARCT) Reports Q2 Loss, Beats Revenue Estimates

Arcturus Therapeutics Q2 Earnings Call Highlights

Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress

Videos

No Data

Press releases

Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress